XRTX Stock Chart & Stats
$0.58
-$0.02(-1.68%)
At close: 4:00 PM EST
$0.58
-$0.02(-1.68%)
Day’s Range― - ―
52-Week Range$1.73 - $7.05
Previous CloseN/A
Volume19.17K
Average Volume (3M)3.79M
Market Cap
$3.64M
Enterprise Value$3.22
Total Cash (Recent Filing)$250.45K
Total Debt (Recent Filing)$15.07K
Price to Earnings (P/E)―
Beta0.51
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,730,565
10 Day Avg. Volume11,302,330
30 Day Avg. Volume3,791,937
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$2.33M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low reported debt materially reduces near-term financial risk for a clinical-stage developer. Low leverage improves flexibility to time financing, limits interest burden, and preserves optionality to fund trials or partnerships without immediate solvency pressure, a durable balance-sheet benefit.
Narrowing LossesMeaningful reduction in operating losses versus 2022 suggests structurally lower burn and improved cost discipline across R&D and G&A. Sustained progress in narrowing losses increases runway per financing round and improves chances of surviving to key clinical readouts or licensing events.
Focused Clinical StrategyA concentrated pipeline targeting kidney and metabolic disorders provides strategic clarity and scientific specialization. Focused expertise can lead to efficient trial design, clearer regulatory pathways and potential niche competitive advantage in an area with persistent unmet needs, supporting long-term relevance.
Bears Say
No RevenueAbsence of product revenue means the company cannot self-fund operations and remains fully dependent on external capital. For a clinical-stage biotech with multi-year development timelines, persistent losses without commercialization create sustained dilution and execution risk for investors and stakeholders.
Persistent Cash BurnNegative operating and free cash flow in every period shows continuing structural cash consumption. Ongoing burn forces frequent financing or partnership dependency, compresses strategic options, and raises the probability of funding-driven delays or program prioritization decisions over the next several quarters.
Shrinking Equity BaseMaterial decline in shareholders' equity signals accumulated losses and/or dilution that weakens the capital cushion. A thinner equity base reduces capacity to absorb adverse events, increases reliance on new issuances, and structurally elevates financing risk for ongoing clinical development.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $1.73 and its highest was $7.05 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is $3.64M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 24 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on XORTX Therapeutics Inc dividends here
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,730,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -$0.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.686%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
Technical Analysis
Ownership Overview
7.33%
Insiders
0.87% Other Institutional Investors
91.81% Public Companies and
Individual Investors